PMC:7601109 / 5056-5377 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T97716","span":{"begin":309,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A74296","pred":"fma_id","subj":"T97716","obj":"http://purl.org/sig/ont/fma/fma12278"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T82771","span":{"begin":0,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T7480","span":{"begin":5,"end":6},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T18967","span":{"begin":56,"end":62},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T49570","span":{"begin":223,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0001195"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":288,"end":300},"obj":"Chemical"},{"id":"T16","span":{"begin":302,"end":316},"obj":"Chemical"},{"id":"T17","span":{"begin":309,"end":316},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_17347"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_37845"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_24621"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T76041","span":{"begin":302,"end":308},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}

{"project":"LitCovid-sentences","denotations":[{"id":"T31","span":{"begin":5,"end":186},"obj":"Sentence"},{"id":"T32","span":{"begin":187,"end":230},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}

{"project":"LitCovid-PubTator","denotations":[{"id":"106","span":{"begin":302,"end":316},"obj":"Gene"},{"id":"112","span":{"begin":97,"end":107},"obj":"Chemical"},{"id":"113","span":{"begin":109,"end":115},"obj":"Chemical"},{"id":"114","span":{"begin":118,"end":127},"obj":"Chemical"},{"id":"115","span":{"begin":129,"end":136},"obj":"Chemical"},{"id":"116","span":{"begin":139,"end":150},"obj":"Chemical"},{"id":"117","span":{"begin":152,"end":160},"obj":"Chemical"},{"id":"118","span":{"begin":288,"end":300},"obj":"Chemical"}],"attributes":[{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"Gene:81668"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"MESH:C000596367"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:C000596367"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"MESH:C547106"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"MESH:D013739"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and"}